Cargando…

Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) commonly presents at advanced stage. We previously reported systemic treatment uptake in stage IV NSCLC climbing from 55% (2009–2012) to 62% (2015–2017). Since then, first-line immunotherapy and 2nd/3rd generation tyrosine kinase inhibitors (TKIs) have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stock-Martineau, Sophie, Laurie, Katie, McKinnon, Mathieu, Zhang, Tinghua, Wheatley-Price, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816185/ https://www.ncbi.nlm.nih.gov/pubmed/33704175 http://dx.doi.org/10.3390/curroncol28010008

Ejemplares similares

What Attributes Matter Most in Physicians? Exploratory Findings from a Single-Centre Survey of Stakeholder Priorities in Cancer Care at a Canadian Academic Cancer Centre
por: Chowdhury, Deepro, et al.
Publicado: (2023)

The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience
por: Karol, Dalia, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy
por: Saint-Pierre, Mathieu D., et al.
Publicado: (2015)

Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report
por: Wong, Boaz, et al.
Publicado: (2022)

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
por: Ezeife, Doreen A., et al.
Publicado: (2022)

Regulatory Evolution and Voltage-Gated Ion Channel Expression in Squid Axon: Selection-Mutation Balance and Fitness Cliffs
por: Kim, Min, et al.
Publicado: (2015)

Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma
por: Bulbul, Yilmaz, et al.
Publicado: (2010)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

TIGAR Is Correlated with Maximal Standardized Uptake Value on FDG-PET and Survival in Non-Small Cell Lung Cancer
por: Zhou, Xiang, et al.
Publicado: (2013)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada
por: McKinnon, Britt, et al.
Publicado: (2021)

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018
por: Wolf, Andrea, et al.
Publicado: (2023)

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
por: Leung, Bonnie, et al.
Publicado: (2023)

Not Waiting to Progress; How the COVID-19 Pandemic Nudged Neoadjuvant Therapy for Stage III Locally Advanced Melanoma Patients
por: Kinaschuk, Katie, et al.
Publicado: (2023)

Baseline tumour measurements predict survival in advanced non-small cell lung cancer
por: Gerber, D E, et al.
Publicado: (2013)

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival
por: Kanaji, Nobuhiro, et al.
Publicado: (2016)

Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer
por: Jo, Hyunji, et al.
Publicado: (2022)

Association of heartbeat complexity with survival in advanced non-small cell lung cancer patients
por: Wu, Shuang, et al.
Publicado: (2023)

Uptake and Tolerance of Chemotherapy in Elderly Patients with Small Cell Lung Cancer and Impact on Survival
por: Fisher, Stacey, et al.
Publicado: (2012)

Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer
por: Carroll, Nikki M., et al.
Publicado: (2023)

Small-cell lung cancer: initial treatment with sequential hemi-body irradiation VS 3-drug systemic chemotherapy.
por: Urtasun, R. C., et al.
Publicado: (1982)

Spectrum: a model platform for linking maternal and child survival interventions with AIDS, family planning and demographic projections
por: Stover, John, et al.
Publicado: (2010)

A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease
por: Xiu, Weigang, et al.
Publicado: (2023)

The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma
por: Kokeza, Josipa, et al.
Publicado: (2023)

Management of Very Early Small Cell Lung Cancer: A Canadian Survey Study
por: Malakouti-Nejad, Bayan, et al.
Publicado: (2023)

The Value of Hope: Patients’ and Physicians’ Preferences for Survival in Advanced Non-Small Cell Lung Cancer
por: Hauber, Brett, et al.
Publicado: (2020)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Wu, Yahua, et al.
Publicado: (2021)

Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer
por: Ebinç, Senar, et al.
Publicado: (2023)

Prognostic impact of maximum standardized uptake value on (18)F‐FDG PET/CT imaging of the primary lung lesion on survival in advanced non‐small cell lung cancer: A retrospective study
por: Qiu, Xiaoling, et al.
Publicado: (2021)

The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy
por: Badaoui, Sarah, et al.
Publicado: (2022)

Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
por: Lee, Dong Soo, et al.
Publicado: (2013)

The Evolution of Therapies in Non-Small Cell Lung Cancer
por: Boolell, Vishal, et al.
Publicado: (2015)

Tumor evolution in non-small-cell lung cancer
por: Parry, Marina
Publicado: (2018)

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
por: Toschi, Luca, et al.
Publicado: (2017)

The evolution of non-small cell lung cancer metastases in TRACERx
por: Al Bakir, Maise, et al.
Publicado: (2023)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
por: Arrieta, Oscar, et al.
Publicado: (2016)

Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer
por: Lee, Sookyung, et al.
Publicado: (2017)

Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
por: Aldarouish, Mohanad, et al.
Publicado: (2019)

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
por: Takayama, Koichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_72pb0oqva6jnh7lgjv8clpd0vt